ABC | Volume 114, Nº5, Maio 2020

Posicionamento Posicionamento da Sociedade Brasileira de Cardiologia para Gravidez e Planejamento Familiar na Mulher Portadora de Cardiopatia – 2020 Arq Bras Cardiol. 2020; 114(5):849-942 315. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet. 2005;366(9499):1797-803. 316. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335(7627):974. 317. Ahmed R, Dunford J, Mehran R, Robson S, Kunadian V. Pre-eclampsia and future cardiovascular risk among women: a review. J AmColl Cardiol. 2014;63(18):1815-22. 318. Silversides CK, Harris L, Haberer K, Sermer M, Colman JM, Siu SC. Recurrencerates ofarrhythmiasduringpregnancy inwomenwithprevious tachyarrhythmiaand impacton fetalandneonataloutcomes.Am JCardiol. 2006;97(8):1206-12. 319. Li JM,NguyenC, Joglar JA,HamdanMH,PageRL.Frequencyandoutcome of arrhythmias complicating admission during pregnancy: experience froma high-volume and ethnically-diverse obstetric service. Clin Cardiol. 2008;31(11):538-541. 320. VaidyaVR,AroraS,PatelN,BadhekaAO,PatelN,AgnihotriK,etal.Burden of arrhythmia in pregnancy. Circulation. 2017;135(6):619-21. 321. Al-Khatib SM, StevensonWG, AckermanMJ, Gillis AM, BryantWJ, Hlatky MA et al. 2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2018;138(13):e272-391. 322. Dan G, Martinez-Rubio A, Agewall S, Boriani G, Borggrefe M, Gaita F, et al. Antiarrhythmic drugs. Clinical use and clinical decision making: a consensus document of EuropeanHeart RhythmAssociation (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart RhythmSociety (HRS), Asia-Pacific HeartRhythmSociety (APHRS)and InternationalSocietyofCardiovascular Pharmacotherapy (ISCP). Europace. 2018;20(5):731-2. 323. Shotan A, Ostrzega E, Mehra A, Johnson JV, Elkayam U. Incidence of arrhythmias in normal pregnancy and relation to palpitations, dizziness, and syncope. Am J Cardiol. 1997;79(8):1061-4. 324. Pijuan-Domenech A, Galian L, Goya M, Casellas M, Merced C, Ferreira-Gonzalez I, et al. Cardiac complications during pregnancy are better predicted with the modified who risk score. Int J Cardiol. 2015 Sep;195:149-54. 325. Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With SupraventricularTachycardia:AReportoftheAmericanCollegeofCardiology/ American Heart Association Task Force on Clinical Practice Guidelines and theHeart RhythmSociety. J AmColl Cardiol. 2016;67(13):e27-115. 326. Wang YC, Chen CH, SuHY, YuMH. The impact of maternal cardioversion on fetal hemodinamics. Eur J Obstet Gynecol Reprod Biol. 2006; 126(2):268-9. 327. Joglar JA, Page RL. Management of arrhythmia syndromes during pregnancy. Curr Opin Cardiol. 2014;29(1):36-44. 328. Kozluk E, Piatkowska A, Kiliszek M, Lodzinski P, Malkowska M, Balsam P, et al. Catheter ablation of cardiac arrhythmias in pregnany without fluoroscopy: a case control retrospective study. Adv Clin Exp Med. 2017;26(1):129-34. 329. HidakaN,ChibaY,FukushimaK,WakeN.Pregnantwomenwithcomplete atrioventricular block: perinatal risks and review of management. Pacing Clin Electrophysiol. 2011;34(9):1161-76. 330. Miyoshi T, Kamiya CA, Katsuragi S, Ueda H, Kobayashi Y, Horiuchi C, et al. Safety and efficacy of implantable cardioverte-defibrillator during pregnancy and after delivery. Circ J. 2013;77(5):1166-70. 331. January CT, Wann S, Alpert JS, Calkins H, Cigarroa JE, Cleveland Jr JC, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/AmericanHeart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071-104. 332. Hoeltzbein M, Beck E, Meixner K. Pregnancy outcome after exposure to the novel oral anticoagulante rivaroxaban in women at suspected risk for thromboembolic events: a case series from the german embryotoxic pharmacovigilance centre. Clin Res Cardiol. 2016;105(2):117-26. 333. Beyer-Westendorf J, Michlaski F, Titti L, Middeldorp S, Cohen H, Abdul Kadir R, et al. Pregnancy outcome in patients exposed to direct oral anticoagulats - and the challenge of event reporting. Thromb Haemost. 2016;116(4):651-8. 334. van der Pol LM, Tromeur C, Bistervels IM, NI Ainle F, van Bemmel T, Bertoletti L, et al. Pregnancy -adapted YEARS Algorithm for Diagnosis of Suspect Pulmonary Embolism. N Engl J Med. 2019; 380(12):1139-49. 335. Brasil. Ministério da saúde. Portal da Saúde. Datasus. [Internet]. [Citado em 2018 dez 10]. Disponível em: www.datasus. gov. br/DATASUS 336. James A; Committee on Practice Bulletins—Obstetrics. Practice Bulletin Não. 123: Thromboembolism in Pregnancy. Obstet Gynecol. 2011;118(3):718-29. 337. Sultan AA, Tata LJ, West J, Fiaschi L, Fleming KM, Nelson-Piercy C, et al. Risk Factors for first venous thromboembolism around pregnancy: a population-based cohort study from the United Kingdom. Blood. 2013;121(19):3953-61. 338. ACOGPractice BulletinNão. 197: Inherited thrombophilias in pregnancy. Obstet Gynecol. 2018;132(1):e18-34. 339. Baglin T, Gray E, Greaves M, Hunt BJ, Keeling D, Machin S, et al. Clinical guidelines for teste for heritable thrombophilias. Br J Haematol. 2010;149(2):209-20. 340. Wan T, Skeith L, Karovitch A, Rodger M, Le Gal G. Guidance for the diagnosis of pulmonary embolism during pregnancy: Consensus and controversies. Thromb Res. 2017 Sep;157:23-8. 341. ChanWS. Diagnosis of venous thromboembolism in pregnancy. Thromb Res. 2018 Mar;163:221-8. 342. MurphyN,BroadhurstDI,KhashanAS,GilliganO,KennyLC,O'Donoghue K. Gestation-specific D-dimer reference ranges: a cross-sectional study. BJOG. 2015;122(3):395-400. 343. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e691S-736S. 344. Mogos MF, Piano MR, McFarlin BL, Salemi JL, Liese KL, Briller JE. Heart Failure in PregnantWomen: AConcern Across the Pregnancy Continuum. Circ Heart Fail. 2018;11(1):e004005. 345. Rohde LE, MonteraMW, Bocchi EA, Clausell Não, AlbuquerqueDC, Rassi S. Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda. Arq Bras Cardiol. 2018;111(3):436-539. 346. Anthony J, Sliwa K. DescompensatedHeart Failure in Pregnancy. Card Fail Rev. 2016;2(1):20-6. 347. Grewal J, Siu SC, Ross HJ, Mason J, Balint OH, Sermer M, et al. Pregnancy outcomes in women with dilated cardiomyopathy. J Am Coll Cardiol. 2009;55(1):45-52. 348. Tanous D, Siu SC, Mason J, Greutmann M, Wald RM, Parker JD, et al. B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol. 2010;56(15):1247-53. 349. Howlett JG, McKelvie RS, Costigan J, Ducharme A, Estrella-Holder E, Ezekowitz JA, et al. The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. Can J Cardiol. 2010;26(4):185-202. 350. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA, et al. 2014 AHA/ACC Guideline for the Management of Patients With 939